The AVENIO Tumor Tissue Expanded Kit is an NGS assay for expanded profiling of solid tumors in formalin-fixed paraffin-embedded (FFPE) tissue samples.  This assay contains 77 genes in the U.S. National Comprehensive Cancer Network (NCCN)¹ and other guidelines, plus 60 emerging biomarkers investigated in clinical trials.

Features and Benefits of AVENIO Tumor Tissue Expanded Kits 

• Panel content exactly-matched to gene panel in the AVENIO ctDNA Expanded Kit (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis between tissue and plasma
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity¹
• 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with the assay
• Flexibility to switch between tissue and plasma to support a variety of research applications
• A streamlined, end-to-end workflow from extraction to analysis and reporting in 5 days
• A turnkey solution that includes reagents, intuitive analysis and reporting to facilitate in-house adoption of high performance NGS oncology testing